The valuation of biotechnology and healthcare firms is closely tied to the projected value of the drug within their pipelines. This value is influenced by a wide range of factors, including expected pricing, market penetration, intellectual property protection, and patent expiration timelines. Valuation becomes even more complex when drugs are still in the clinical phase, where the outcome — and thus the value — is closely linked to the inherent risks of ongoing clinical trials.
 
We specialize in evaluating these critical parameters at both the clinical and commercial stages. By integrating these insights with a firm’s financial data, we deliver clear, robust valuations that accurately reflect the company's true potential.